|
Through
a series of acquisitions, Albea Pharmaceuticals
intends
to build a rapidly growing, profitable, and fully integrated
pan-European pharmaceutical company with a portfolio of marketed
products, a direct sales and marketing organization in the major
European countries (UK, Germany, France, Italy and Spain), and a
pipeline of products in various stages of clinical
development.
Acura
Pharmaceuticals
(formerly Halsey Pharmaceuticals) is a specialty pharmaceutical
development company engaged in research, development and manufacture
of innovative abuse deterrent, abuse resistant and tamper resistant
formulations
(the "Aversion® Technology") intended for use in
orally administered opioid-containing prescription analgesic products.
AmeriFIT Nutrition Inc.
is a cutting edge, innovative leader in the nutritional supplement
industry, focused on building brands in the burgeoning women's health
and joint care categories.
Using its proprietary CORPLEX hydrogel technology, Corium International develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. Corium's product development and manufacturing expertise include Rx transdermal systems, OTC, personal care and wound care products, products requiring pressure-sensitive adhesives and medical diagnostics and devices.
Dow
Pharmaceutical Sciences
specializes in development of topical drug products for pharmaceutical
and biotechnology clients.
EUSA Pharma Inc
is a new specialty pharmaceutical company focused on the major European
countries. EUSA intends to build a portfolio of products that are on the
market or in late-stage clinical trials through acquisitions and
in-licensing from the US. The Company will build a sales and marketing
organization and commercial infrastructure in all major European
countries.
Healthcare Brands International (HBI) is a company established in
the UK in October 2006, which participates primarily in the growing
market of OTC Medicines. HBI is committed to acquiring, developing and
investing in differentiated healthcare products, to translate innovative
science into meaningful consumer brands..
Horizon Therapeutics is a late stage biopharmaceutical company focused on rapid development of prescription drugs for mild to moderate pain relief. They create novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
MediciNova, Inc.
is a pharmaceutical company that
creates value by in-licensing compounds from predominantly small to
mid-sized Japanese pharmaceutical companies
and advancing the clinical development of these in-licensed compounds by
conducting further trials throughout the world. MediciNova’s current
drug pipeline includes proprietary compounds that are in late-stage
clinical trials (Phase II or Phase III) in the following indications:
asthma,multiple sclerosis, cancer, anxiety disorders, and interstitial
cystitis. The Company is listed on the Osaka (Hercules) Securities
Exchange, Code number: 4875.
Palatin
is an emerging leader in pharmaceutical research and development in the
areas of drug discovery, pre-clinical/clinical research and product
development.
Palmetto Pharmaceuticals
(formerly eNOS
Pharmaceuticals) has developed products that improve and restore blood
flow and to reduce triglycerides through up-regulation of endothelial
nitric oxide synthase (eNOS) enzyme. The Company's first drug
candidate, L-arginine Sustained Release for the management of
hypertriglyceridaemia, is in clinical trials in Germany.
Prism
Pharmaceuticals
is a near-commercial stage specialty pharmaceutical company based in King of Prussia, Pennsylvania, focused on developing novel, differentiated pharmaceuticals for use in the $8 billion acute cardiovascular
market. Prism's risk-mitigated approach to drug development has focuses on unfulfilled opportunities in already commercialed products, leading to well defined clinical and regulatory pathways for each of its compounds.
Receptor BioLogix, Inc.
is a biopharmaceutical company focused on the development and commercialization of a newly discovered class of
protein therapeutics called Intron Fusion Proteins (IFP) to treat
cancer, autoimmune, metabolic and other diseases.
Revance Therapeutics
is a specialty pharmaceutical company formed to discover, develop and
commercialize therapeutic products for treating chronic disease and
age-related changes to skin and soft tissue. The Company's core clinical
targets are in areas of aesthetic medicine and therapeutic dermatology.
Salix Pharmaceuticals, Ltd.
is a leading specialty pharmaceutical company providing solutions to
gastroenterologists and their patients.
Shire Pharmaceuticals Group
is an international specialty pharmaceutical company with a strategic
focus on four therapeutic areas: central nervous system disorders,
metabolic diseases, oncology and gastroenterology.
Victory Pharma, Inc. is a privately held specialty pharmaceutical company that is focused on acquiring, developing and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN (naproxen sodium) Controlled-Release Tablets and other pain products to pain management specialists, rheumatologists, orthopedic surgeons and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common, opiate-induced side effects.
Xanodyne Pharmacal, Inc.
is a fully integrated, specialty pharmaceutical company that acquires,
develops, and markets prescription pharmaceutical products in the
women's health and pain management markets. Xanodyne Pharmaceuticals was
formed from the merger of Xanodyne Pharmacal and Integrity
Pharmaceuticals in February 2004.
ZIOPHARM Oncology is
a biopharmaceutical company engaged in the development and
commercialization of a diverse, risk-sensitive portfolio of in-licensed
cancer drugs to address unmet medical needs.
|
